Drug
AQW051
AQW051 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 83.3%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
83.3%
Based on 5 completed trials
Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_2
3
50%
Ph phase_1
3
50%
Phase Distribution
3
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
83.3%
5 of 6 finished
Non-Completion Rate
16.7%
1 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(5)
Terminated(1)
Detailed Status
Completed5
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (50.0%)
Phase 23 (50.0%)
Trials by Status
terminated117%
completed583%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_1
Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
NCT00825539
completedphase_2
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
NCT01474421
completedphase_2
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
NCT01730768
terminatedphase_2
Effect of AQW051 in Patients With Memory Impairment
NCT00582855
completedphase_1
Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.
NCT00418002
Clinical Trials (6)
Showing 6 of 6 trials
NCT00825539Phase 1
Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
NCT01474421Phase 2
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
NCT01730768Phase 2
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
NCT00582855Phase 2
Effect of AQW051 in Patients With Memory Impairment
NCT00418002Phase 1
Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.
NCT00409500Phase 1
Effect of Food on the Pharmacokinetics of AQW051 in Japanese Healthy Male Subjects
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6